Imaging of Human Tumor Xenografts With an Indium-111-Labeled Anti-Epidermal Growth Factor Receptor Monoclonal Antibody

• Published in: JNCI : Journal of the National Cancer Institute 1989-11, Vol.81 (21), p.1616-1625
• Main Authors: Goldenberg, Alec, Masui, Hideo, Divgi, Chaitanya, Kamrath, Heidi, Pentlow, Keith, Mendelsohn, John
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Monoclonal; ErbB Receptors - analysis; ErbB Receptors - immunology; Female; Humans; Indium Radioisotopes; Infant; Mammary Neoplasms, Experimental - diagnostic imaging; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental - diagnostic imaging; Radionuclide Imaging; Transplantation, Heterologous; Vulvar Neoplasms - diagnostic imaging
• ISSN: 0027-8874; 1460-2105
• DOI: 10.1093/jnci/81.21.1616

The mouse monoclonal antibody (mAb) 225 IgG1 against the epidermal growth factor (EGF) receptor has been investigated for its capacity to localize in human tumor xenografts. The EGF receptor is the product of the c-erb-B proto-oncogene (also known as EGFR). Elevated expression of EGF receptors has been demonstrated in many human tumors and tumor cell lines. We studied A431 human vulvar squamous cell carcinoma cells, with 2 × 106 receptors per cell; MDA-MB-468 (MDA 468) human breast adenocarcinoma cells, with 3 × 105 receptors per cell; and MCF-7 human breast adenocarcinoma cells, with 5 × 103 receptors per cell. The 111In-labeled pentetic acid (DTPA), derivative of mAb 225 (111In-DTPA-225) was injected intraperitoneally into nude mice bearing subcutaneous tumor xenografts. We measured uptake by quantifying radioactivity in tumor and normal tissues and by obtaining gamma camera images. Uptake in A431 xenografts was 28% ± 2.4% of the injected dose per gram of tumor on day 3 and 12.4% ± 3.0% on day 7. Distribution ratios comparing uptake in the tumor with that in normal tissues were consistently greater than 4. In contrast, there was far less uptake of the control mAb KS1/4S-1 labeled with 111In. This conjugate, 111In-DTPA-KS1/4S-1, has an IgG1 isotype but does not bind to human or murine cells. Imaging of the tumor with mAb 225 was excellent, especially on days 3–7. MDA 468 xenografts exhibited reduced localization of mAb 225 in the tumor. For MCF-7 xenografts, the tumor uptake of mAb 225 after 7 days was only 0.70% ± 0.10% of the injected dose per gram of tumor, which was comparable to the uptake of the KS1/4S-1 control mAb. The ratio of the concentration of radioactivity in the tumor to that in normal tissue (distribution ratio) showed poor selectivity of uptake, and imaging was not obtained. These observations suggest that labeled mAb can target the product of a proto-oncogene, the EGF receptor, when it is expressed at high levels in human tumor xenografts. [J Natl Cancer Inst 81:1616–1625, 1989]